title: Adenosine A2(A) receptor modulates the oxidative stress response of primed polymorphonuclear leukocytes after parabolic flight.
abstract: Space flight and gravitational stress can alter innate immune function. Parabolic flights (PFs) as a model for short-term gravitational changes prime the cytotoxic capability of polymorphonuclear leukocytes (PMNs). In view of the emerging role of adenosine in the regulation of innate immune responses, we examined the potency of adenosine to control the release of cytotoxic H(2)O(2) by primed PMNs via the adenosine receptor system. During PFs, microgravity conditions (<10(-2) G) are generated for approximately 22 seconds, followed by a hypergravity (1.8 G) phase resulting in gravitational stress. We studied the ex vivo effects of adenosine on the production of H(2)O(2) by stimulated PMNs and determined adenosine plasma levels and adenosine A2(A) receptor transcripts of leukocytes of PF participants (n = 15). Increasing concentrations of adenosine dose dependently reduced tissue-toxic H(2)O(2) production by PMNs with a half-maximal inhibitory concentration (IC(50)) of 19.5 nM before takeoff and 7.6 nM at 48 hours after PF. This increase in the adenosine-mediated inhibition of PMNs' H(2)O(2) production was completely reversed by addition of the A2(A) receptor antagonist ZM241385. PF induced a nonsignificant elevation in adenosine plasma levels; A2(A) receptor mRNA from leukocytes remained almost unchanged. Adenosine limits the oxidative stress response of PMNs after PFs through an upregulation of the adenosine A2(A) receptor function. This stop signal on inflammation is stronger than that under normal physiologic states and may limit further cytotoxic damage. Pharmacologic manipulation of the adenosine A2(A) receptor pathway could be a potential target for control of unwanted exacerbations of cytotoxic PMN functions.
authors.affiliation: Department of Anaesthesiology, University of Munich, 81366 Munich, Germany.
authors.forename: Ines
authors.initials: I
authors.lastname: Kaufmann
authors.forename: Matthias
authors.initials: M
authors.lastname: Feuerecker
authors.forename: Alex
authors.initials: A
authors.lastname: Salam
authors.forename: Gustav
authors.initials: G
authors.lastname: Schelling
authors.forename: Manfred
authors.initials: M
authors.lastname: Thiel
authors.forename: Alexander
authors.initials: A
authors.lastname: Choukèr
mesh_terms: D000241:Adenosine / Q000097:blood / Q000494:pharmacology*; D058917:Adenosine A2 Receptor Antagonists / Q000494:pharmacology; D000328:Adult; D005786:Gene Expression Regulation / Q000276:immunology; D018470:Gravity, Altered / Q000009:adverse effects; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007155:Immunologic Factors / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D043683:Receptors, Adenosine A2 / Q000235:genetics / Q000276:immunology*; D014227:Triazines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D007155:Immunologic Factors; D012333:RNA, Messenger; D043683:Receptors, Adenosine A2; D014227:Triazines; D014230:Triazoles; D014409:Tumor Necrosis Factor-alpha; D014665:Vasodilator Agents; C097270:ZM 241385; D009240:N-Formylmethionine Leucyl-Phenylalanine; D006861:Hydrogen Peroxide; D000241:Adenosine